Category survey

Capillary electrophoresis based high-throughput system for beta-secretase inhibitor screening as a therapeutic target of Alzheimer’s disease Investments < €500k Czech Republic 2016    

Cognitive predictors of neurodegeneration Investments < €500k Czech Republic 2016    

Multidisciplinary approach in the diagnosis of frontotemporal lobar degenerations and tauopathies: new insights into pathogenetic mechanisms Investments < €500k Czech Republic 2016    

Markers of neurodegeneration in differential diagnosis of parkinsonian syndrome Investments < €500k Czech Republic 2016    

Diagnostic markers and pathophysiological mechanisms of atypical parkinsonian syndromes Investments < €500k Czech Republic 2016    

Brief psychometric instruments for early diagnosis of Alzheimer’s disease in senior population Investments < €500k Czech Republic 2016    

VASCULAR FACTORS IN PREDICTION OF ALZHEIMER’S DISEASE Investments < €500k Czech Republic 2016    

Speech, its impairment and cognitive performance in Parkinson’s disease Investments < €500k Czech Republic 2016    

New diagnostic approaches to Creutzfeldt-Jakob disease Investments < €500k Czech Republic 2016    

Analysis of bradykinesia and speech in Parkinson’s disease Investments < €500k Czech Republic 2016    

Epidemilogical study of the prevalence of neurodegenerative parkinsonism Investments < €500k Czech Republic 2016    

’Dopamine Transporter Deficiency Syndrome’: a new cause of parkinsonism and neuropsychiatric disease Investments < €500k Denmark 2016    

Magnetic resonance imaging biomarkers in Alzheimer’s disease: investigating capillary dysfunction and neurodegeneration for diagnosis and prediction Investments < €500k Denmark 2016    

Mannose 6 Phosphate Receptor as a Target for Disease-modifying Therapies in Parkinson’s Disease Investments < €500k Denmark 2016    

REGULATION OF SORLA IN GENERAL AND IN ALZHEIMER´S DISEASE Investments < €500k Denmark 2016    

ZINC AND COPPER SITES IN ALZHEIMER’S DISEASE Investments < €500k Denmark 2016    

Improving Performance in Drivers with Mild Cognitive Impairment: An RCT of Cognitive Training Investments < €500k Canada 2016    

Understanding memory changes and brain plasticity in mild cognitive impairment Investments < €500k Canada 2016    

Multimodal Assessment For Predicting Specific Pathological Substrate in Frontotemporal Lobar Degeneration Investments < €500k Canada 2016    

The neural circuitry of executive functions in Parkinson’s disease Investments < €500k Canada 2016    

Causal relationship between a LC-omega-3-enriched diet and cognition Investments < €500k Canada 2016    

Predicting outcome in Parkinson’s disease cognitive impairment Investments < €500k Canada 2016    

Caffeine as a Therapeutic Agent in Parkinson’s disease Investments < €500k Canada 2016    

Early and preclinical diagnosis of Parkinson’s disease using olfactory testing and Diffusion Tensor Imaging of olfactory bulb and substantia nigra. Investments < €500k Canada 2016    

Mechanisms by which Afferents Regulate Striatal Neuronal Loss and Motor Activity in Movement Disorders Investments < €500k Canada 2016    

The impact of beta-amyloid burden on cognition in normal aging Investments < €500k Canada 2016    

Reshaping the Path of Mild Cognitive Impairment by Refining Exercise Prescription: Understanding Training Type and Exploring Mechanisms Investments < €500k Canada 2016    

Biomarkers of Vascular Function and Integrity in Cerebral Amyloid Angiopathy: A Prospective Longitudinal Cohort Study Investments < €500k Canada 2016    

Cognitive complications in Parkinson’s disease: the contribution of dopamine. Investments < €500k Canada 2016    

Comparing the nature and evolution of Mild Cognitive Impairment in individuals with and without Parkinson’s disease. Investments < €500k Canada 2016    

Tau in Central Nervous System: neurotoxic and autoimmune component Investments < €500k Czech Republic 2016    

Search of mechanisms responsible for adverse effects of amyloid beta on muscarinic receptor transmission Investments < €500k Czech Republic 2016    

Intrathecal and intramuscular application of mesenchymal stem cells and their secretome in the treatment of amyotrophic lateral sclerosis Investments < €500k Czech Republic 2016    

Neuroprotective effects of novel analogs of anorexigenic prolactin-releasing peptide (PrRP) in mouse models of neurodegeneration and obesity Investments < €500k Czech Republic 2016    

REM sleep behavior disorder: predicting the risk of neurodegeneration Investments < €500k Czech Republic 2016    

Novel hybrid compounds in the cognitive decline caused by neurodegeneration Investments < €500k Czech Republic 2016    

Modulating Blood Vessel Growth in Alzheimer’s Disease Investments < €500k Canada 2016    

Mechanisms of therapeutic efficacy of deep brain stimulation in Parkinson’s disease Investments < €500k Canada 2016    

Alzheimer Disease Pathobiology and Mechanisms of Neurodegeneration Investments < €500k Canada 2016    

Regulation of Metabotropic Glutamate Receptor Scaffolded Signaling Complexes Investments < €500k Canada 2016    

Targeted delivery into brain capillary endothelial cells for the treatment of Alzheimer disease Investments < €500k Canada 2016    

Validation of the human farnesyl pyrophosphate synthase (hFPPS) as a therapeutic target and design of pre-clinical candidates for the treatment of multiple myeloma and neurodegenerative diseases. Investments < €500k Canada 2016    

Prion Protein Proteostasis Investments < €500k Canada 2016    

Prefrontal attention circuitry: Mechanisms of deregulation and restoration in brain disorders Investments < €500k Canada 2016    

Organisation anatomique et fonctionnelle du striatum en conditions normale et pathologiques Anatomical and functional organization of the striatum under normal and pathological conditions Investments < €500k Canada 2016    

Roles of cardiotrophin-like cytokine partners in the immune response Investments < €500k Canada 2016    

Stimulation cérébrale dans la maladie de Parkinson: mécanismes d’action et implication clinique. Brain stimulation in Parkinson’s disease: mechanisms of action and clinical involvement Investments < €500k Canada 2016    

Self-propagating protein aggregates in Alzheimer’s disease Investments < €500k Canada 2016    

Amyloid-beta regulation of hippocampal synaptic plasticity Investments < €500k Canada 2016    

Mutant protein spread in Huntington’s disease and its implications for other neurodegenerative disorders of the CNS. Investments < €500k Canada 2016